Real-World Prescribing Patterns of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Older Adults with Type 2 Diabetes and Cardiometabolic Disease
Ibrahim S. Alhomoud, Khalid A. Alamer · 2025
Read Real-World Prescribing Patterns of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Older Adults with Type 2 Diabetes and Cardiometabolic Disease by Ibrahim S. Alhomoud, Khalid A. Alamer (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12845426.txt.
Description
Ibrahim Alhomoud and Khalid Alamer audited how often two modern diabetes drug classes reach the older patients guidelines say should get them. SGLT2 inhibitors and GLP-1 receptor agonists protect the heart and kidneys, and guidelines urge them for patients with cardiovascular or kidney disease. The team reviewed records of older adults at a Saudi tertiary hospital from 2019 to 2023.
Among patients documented as high-risk, eighty-three percent received one of the drugs, a strong rate. The catch was documentation itself: only a small share of older patients were recorded as having the qualifying diseases at all, so overall use stayed low. Older age, female sex, and unmarried status lowered the odds of treatment. The authors argue better detection of heart and kidney disease is the real bottleneck.
Catalog record
| CREATOR | Ibrahim S. Alhomoud, Khalid A. Alamer |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 28 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |